Abbott recently earned FDA approval for its latest transcatheter aortic valve implantation (TAVI) system, which is named Navitor. Abbott will have to fight for its place the U.S. TAVI device space, as the systems made by Edwards and Medtronic have a steadfast command of the market share.
Transcatheter aortic valve implantation is a promising next-gen technology for common conditions like aortic stenosis. Irvine-based JenaValve Technology just added another $26.5 million to its Series C round, bringing the devicemaker to nearly $100 million for the round for its TAVI prosthetic valve.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.